Morgan Stanley Maintains Equal-Weight on Fractyl Health, Lowers Price Target to $4

Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Fractyl Health (NASDAQ: GUTS) while significantly lowering the price target from $24 to $4. This adjustment reflects a reassessment of the company's market position and potential.